Prostate Cancer

The phase 1/2a CYPIDES trial assessed the safety and preliminary efficacy of ODM-208 in heavily pretreated patients with metastatic castration-resistant prostate cancer.

The payment rate for the prostate cancer test went into effect on January 1, 2024.

The open-label CaRe PC trial plans to enroll up to 30 adult patients with mCRPC, who will be treated across 3 dose levels of INKmune.

Over a decade of data document a continued increase in the use of hypofractionation in patients with localized prostate cancer.

Over the past year, the FDA approved a multitude of new treatments and devices for use in urology practice.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

"This study, using a novel technology to manage hot flashes, truly moves the field forward in improving the quality of life for men with prostate cancer,” says Alicia K. Morgans, MD, MPH.

Investigators analyzed data from over 1300 patients undergoing treatment for prostate cancer at 5 hospitals.

A prostate imaging expert shares tips for how to interpret PSMA PET/CT imaging results as well as when re-imaging is recommended.

A response by the FDA is expected by February 2024.

Jaideep S. Sohi, MD, discusses how PSMA PET imaging has impacted diagnosis and management of prostate cancer in clinical practice, when and why it should be considered over conventional imaging, and which PSMA PET tracers are available.

Eric J. Small, MD, is an international leader in prostate cancer research and has published more than 430 peer-reviewed articles.

Specialists in the field of prostate cancer discuss their approaches for discussing rectal spacing with patients.

Comprehensive insights on the utilization of rectal spacers with proton beam radiation and brachytherapy in prostate cancer.

Dr. Shawn Zimberg and Dr. Dean Laganosky discuss the BioProtect Balloon Transplant System, a rectal spacer for use in prostate cancer radiation.

Experts on prostate cancer outline the best candidates for rectal spacing and outline factors that influence rectal spacer placement.

Prostate cancer specialists provide insights on stereotactic body radiation therapy (SBRT) and hypofractionation and their relationship to optimal rectal spacing.

“The study highlights the importance of considering how altering cell metabolism could impact prostate cancer and its response to treatment," says Jenna Giafaglione.

“This next-generation rectal spacing option is the first of its kind...and has the potential to provide an enhanced degree of protection from the genitourinary and rectal effects of prostate cancer radiation therapy,” said Dr. Laganosky.

Overall, Black men were 24% less likely to receive or be prescribed a novel hormonal therapy agent compared with White men.

In the third article of this series, Paul E. Dato, MD, provides comprehensive insights on the multidisciplinary care of patients with metastatic castration-resistant prostate cancer.

Urologists offer their perspectives on toxicity seen in patients with prostate cancer who are undergoing radiation treatment.

Experts on prostate cancer discuss the risks, complications, and safety considerations for patients with prostate cancer who are considering radiation therapy.

In this installment, expert Paul E. Dato, MD, discusses the value of a multidisciplinary team in managing patients with mCRPC and considers how his institution ensures patients receive best available therapy.

The research projects are assessing combination therapies in advanced prostate cancer that include the use of relugolix.

Dr Daniel Allan Hamstra highlights ongoing and planned trials investigating rectal spacers in patients with prostate cancer undergoing radiation therapy that he hopes will provide more data on toxicity reduction and preservation of sexual function.

Dr Hamstra recommends rectal spacers in certain prostate cancer patients to reduce rectal toxicity, allow dose escalation, and preserve sexual function, but advises judicious use due to potential complications and lack of long-term quality of life data with newer spacers.

In the second article of this series, Benjamin H. Lowentritt, MD, FACS, provides clinical insights on micronized abiraterone as a treatment for patients with prostate cancer.

The FDA has approved enzalutamide for use with or without a GnRH analog therapy for the treatment of patients with nonmetastatic castration-sensitive prostate cancer.